

**PE/Dazzle™ 594 anti-human CD19**

**Catalog # / Size:** 2111255 / 25 tests  
2111260 / 100 tests

**Clone:** HIB19

**Isotype:** Mouse IgG1, κ


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** V CD19.11

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD19 (clone HIB19) PE/Dazzle™ 594 (filled histogram) or mouse IgG1, κ PE/Dazzle™ 594 isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>8</sup> and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 302214).

**Application References:**

- Schlossman S, *et al.* 1995. Leucocyte Typing V. Oxford University Press. New York.
- Knapp W, *et al.* 1989. Leucocyte Typing IV. Oxford University Press. New York.
- Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.
- Joseph A, *et al.* 2010. *J. Virol.* 84:6645. [PubMed](#)
- Wang X, *et al.* 2010. *Haematologica.* 95:884. (FC) [PubMed](#)
- Walker JD, *et al.* 2009. *J. Immunol.* 182:1548. (Block) [PubMed](#)
- Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
- Hansen A, *et al.* 2002. *Arthritis Rheum.* 46:2160. (IHC)

**Description:** CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a

complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

- Antigen** 1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437.
- References:** 2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.